Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. M.C. Plaz Torres, Q. Lai, F. Piscaglia, E. Caturelli, G. Cabibbo, E. Biasini, F. Pelizzaro, F. Marra, F. Trevisani, E.G. Giannini, Treatment of hepatocellular carcinoma with immune checkpoint inhibitors and applicability of first-line atezolizumab/bevacizumab in a real-life setting. J. Clin. Med. 10, 3201 (2021)
2. Y. Xue, S. Gao, J. Gou, T. Yin, H. He, Y. Wang, Y. Zhang, X. Tang, R. Wu, Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action, Expert opinion on drug delivery, 18 (2021) 187–203
3. F. Zhang, X. Qi, X. Wang, D. Wei, J. Wu, L. Feng, H. Cai, Y. Wang, N. Zeng, T. Xu, Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget. 8, 90215 (2017)
4. K. Du, H. Huang, Development of anti-PD-L1 antibody based on structure prediction of AlphaFold2. Front. Immunol. 14, 1 (2023)
5. M.J. Davies, PD-1/PD-L1 inhibitors for non–small cell lung cancer: incorporating Care Step pathways for effective side-effect management. J. Adv. Practitioner Oncol. 10, 21 (2019)